Boston Scien Cp Stock Price, News & Analysis

Boston Scientific (NYSE: BSX) reported Q3 2025 net sales of $5.065B, up 20.3% reported, 19.4% operational and 15.3% organic versus prior year. GAAP EPS was $0.51 and adjusted EPS was $0.75, above guidance ranges. By segment, Cardiovascular sales were $3.343B (+22.4%) and MedSurg sales were $1.722B (+16.4%). Regional highlights included the U.S. up 27.0% and APAC up 17.1%; EMEA was roughly flat. Company updated full-year 2025 guidance: ~20% reported net sales growth, GAAP EPS $1.97–$2.01, adjusted EPS $3.02–$3.04. Announced completed Elutia asset acquisition and agreement to acquire Nalu Medical.

Boston Scientific (NYSE: BSX) agreed to acquire Nalu Medical for an upfront cash payment of approximately $533 million for remaining equity ($600 million on a 100% basis before Boston Scientific ownership). The deal expands Boston Scientific's neuromodulation portfolio with Nalu's miniaturized, battery-free Nalu Neurostimulation System for peripheral nerve stimulation (PNS), cleared by the FDA 510(k) in 2019.

Clinical data cited: COMFORT 87% >50% pain reduction at 12 months; COMFORT 2 79% of patients with 64% average pain relief at 6 months; real-world data from >2,000 patients with 94% clinically meaningful improvement. Boston Scientific expects close in H1 2026, Nalu sales > $60M in 2025 and >25% YoY growth in 2026; adjusted EPS impact: immaterial 2026, slightly accretive 2027, while GAAP EPS is expected to be dilutive initially.

Boston Scientific (NYSE: BSX) has announced two upcoming investor events. The company will host its 2025 Investor Day on September 30, 2025, at 8:30 a.m. ET in a hybrid format, where management will discuss financial goals and long-term growth strategies.

Additionally, BSX will hold its Q3 2025 earnings conference call on October 22, 2025, at 8:00 a.m. ET. The call will feature Chairman and CEO Mike Mahoney and CFO Jon Monson. Both events will be webcast live and available for replay on the company's investor relations website.

Creative Media and Community Trust (NASDAQ: CMCT) has secured a significant lease agreement with Boston Scientific Corporation (NYSE: BSX) at its Penn Field Campus in Austin, Texas. The approximately 11-year lease covers a 30,821-square-foot building, bringing the property's occupancy to 93%.

The Penn Field Campus, spanning 228,000 square feet across 16 acres in Austin's "SoCo" Business District, is a historic property originally developed in 1918 as a U.S. Army air base. The property has been transformed into a modern office campus while maintaining its historical character, featuring landscaped grounds and diverse tenants from technology, media, and entertainment sectors.

Boston Scientific (NYSE: BSX) reported strong Q2 2025 financial results, with net sales reaching $5.061 billion, representing a 22.8% reported growth and 17.4% organic growth year-over-year. The company achieved GAAP EPS of $0.53 and adjusted EPS of $0.75, both exceeding guidance.

Key segment performance showed robust growth, with Cardiovascular up 26.8% and MedSurg up 15.7% reported. The U.S. market led regional performance with 30.7% growth. Notable developments include FDA approval for expanded FARAPULSE™ PFA System use and strategic acquisitions of Intera Oncology and SoniVie.

The company raised its full-year 2025 guidance to 18-19% reported growth and 14-15% organic growth, with adjusted EPS projected at $2.95-$2.99.

Boston Scientific (NYSE:BSX) has received FDA approval for expanded labeling of its FARAPULSE™ Pulsed Field Ablation (PFA) System to treat persistent atrial fibrillation (AF). The system, which delivers pulsed field energy through a catheter to ablate heart tissue, demonstrated strong clinical results in the ADVANTAGE AF trial with a 85.3% symptomatic AF recurrence-free rate.

The trial, involving 260 patients across 43 global sites, showed no major complications and an improved success rate of 91.4% among experienced physicians. Boston Scientific expects CE mark approval and regulatory clearances in Japan and China soon, while also initiating the ReMATCH IDE trial to study the system's effectiveness in approximately 375 patients across 40 centers in the U.S. and Asia.

Boston Scientific (NYSE:BSX) has scheduled a conference call to discuss its second quarter 2025 financial results and business highlights. The call will take place on July 23, 2025, at 8:00 a.m. ET, featuring Chairman and CEO Mike Mahoney and CFO Jon Monson.

The company will release its Q2 2025 financial results prior to the conference call. Investors can access both the live webcast and replay through the company's investor relations website, with the replay becoming available approximately one hour after the event concludes.

Archimedes Vascular, a pre-clinical stage medical device company, has secured $2.2 million in Series A financing led by Sherpa Healthcare Partners. The company is developing an implant for treating severe hypertension and has appointed Raymond W. Cohen as Chairman of its Board of Directors. Cohen brings significant industry experience, having previously served as CEO of Axonics, which ranked No. 1 on Deloitte Technology Fast 500 and Financial Times fastest-growing companies lists in 2021-2022, before being acquired by Boston Scientific. Cohen also served as Chairman of SoniVie, which was sold to Boston Scientific in March 2025. The funding will support pre-clinical work as Archimedes seeks FDA clearance for initial human clinical studies.

Boston Scientific (NYSE: BSX) has announced its participation in two major investor conferences in May 2025. At the Bank of America's 2025 Health Care Conference on May 13, Dan Brennan (EVP & CFO) and Joe Fitzgerald (EVP & Group President, Cardiology) will engage in a 30-minute Q&A session starting at 8:00 a.m. PT. Later, on May 28, at Bernstein's 41st Annual Strategic Decisions Conference, Chairman & CEO Mike Mahoney and Dr. Ken Stein (SVP & Global Chief Medical Officer) will participate in a 50-minute Q&A session beginning at 8:00 a.m. ET. Both events will be available via live webcast and replay on the company's investor relations website.